Even though Breast Cancer Awareness month is over, perhaps we should reflect on how the disease impacts South African men and women every single day- 1 in 27 women will develop breast cancer in their lifetime, while male breast cancer accounts for 1% of all breast cancer cases – so it is applicable to me and you.
Roche is taking steps to fight the scourge and is inviting women to join them.
#Every30Days inspires and empowers the women of South Africa with the support and advice they need to perform breast self-examinations and its online platform:
https://www.roche.co.za/en/diseaseeducation/Every_30_Days_Breast_Se... provides expert guidance to detect breast cancer in its earliest stage.
“Knowing and understanding one’s body is not just good advice, it’s a health imperative,” says Esnath Muzenda, communication officer at Roche. “#Every30Days encourages women to follow a three-step breast self-exam at www.URL.co.za and make it part of their monthly routine.”
Taking action to diagnose breast cancer early is becoming more and more urgent because the prevalence of this cancer is increasing dramatically. Data from the Global Cancer Observatory shows that the incidence of breast cancer has risen from 1.38 million in 2008 to 2.08 million in 2018.
Early diagnosis is, however, proving key in the fight and the World Health Organization recommends breast self-exams to raise awareness of the disease.
“At Roche, we’re always looking for better ways to prevent, diagnose and treat diseases, which is why it’s so important to us to make more people aware of the importance of early detection,” adds Muzenda. “It’s also why we’ve partnered with Reach for Recovery, a non-profit organisation that supports breast cancer patients across the country.”
Reach for Recovery offers support to both breast cancer fighters and survivors and Roche is involved in the organisation’s Playing for Pink initiative, which takes place in October this year. A large percentage of proceeds will go towards Reach for Recovery's Ditto Project, a powerful, supportive initiative which raises funds to purchase and supply breast prostheses for mastectomy patients who could otherwise not afford them.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
Add a Comment